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Abstract
The first racemic total synthesis of the isoquinoline–benzylisoquinoline alkaloid mur-
aricine is reported herein. Pharmacological characterization identified muraricine as a
moderate inhibitor of P‐glycoprotein, a crucial factor of multidrug resistance in cancer.
When combined with vincristine, muraricine partly reversed the chemoresistance
of vincristine‐resistant leukemia cells at a nontoxic concentration. Furthermore, no
cytotoxic effects on noncancerous human cells in therapeutically relevant concentra-
tions were observed.
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1 | INTRODUCTION
Bisbenzylisoquinolines are a large and structurally diverse subclass of the
widely distributed benzylisoquinoline alkaloids.[1–3] In this chemotype,
typically two tetrahydroisoquinoline units are connected by two (or
more) diaryl ether (in some cases also biaryl) units to result in rigid,
macrocyclic compounds, as exemplified by the structure of tetrandrine
(1).[4] Numerous biological activities have been described for bisbenzyl-
isoquinoline and several monomeric benzylisoquinoline alkaloids includ-
ing anticancer,[5–9] multidrug resistance reversing,[10–15] antiviral,[16,17]
antimicrobial,[18] and calcium channel‐blocking activities.[19,20] Moreover,
seco‐analogues (so‐called seco‐bisbenzylisoquinoline alkaloids) have been
detected, mainly in plants from the families Berberidaceae and Annona-
ceae.[21] There is some evidence that these seco‐bisbenzylisoquinolines of
natural origin are formed by oxidative degradation or by chemical and
enzymatic cleavage[22] of parent bisbenzylisoquinoline alkaloids, probably
as a first step of alkaloid catabolism in plant cells.[23] A couple of artefacts
identical to these alkaloids were obtained by controlled photooxidation of
bisbenzylisoquinoline alkaloids.[24,25]
In these seco‐compounds, one or more bonds of the macrocyclic
bisbenzylisoquinoline core are formally broken, with the most typical
first scission between C‐1 of an isoquinoline ring and the adjacent
benzylic methylene group, as shown for seco‐isotetrandrine (2).[26] But
there are also examples for formal cleavage of a diaryl ether bridge
between two isoquinoline units, as shown for berbamunine (3).[27] The
tetrahydroisoquinolin‐1‐one unit of seco‐bisbenzylisoquinolines (e.g., 2)
can formally be reduced to a tetrahydroisoquinoline, as shown for
chenabine (4), but the mechanism of the biosynthesis is still unclear.[28]
In certain cases, parts of the molecules are lost, as demonstrated for
bargustanine (5),[29] where a complete benzyl unit is missing, and small
“dimeric” isoquinolone alkaloids like berbidine (6),[23,30] in which both
benzyl residues were cleaved off (Figure 1).
Recently, a novel seco‐bisbenzylisoquinoline alkaloid, muraricine
(7), was isolated from Berberis vulgaris (Berberidaceae) by Hostalkova
et al.[31] Based on the analogy with related alkaloids, (R) configuration
was postulated for 7. In this alkaloid, similar to bargustanine (5), a
diaryl ether bridge connecting two isoquinoline units is still present,
and formally one benzyl unit is lost. This compound showed moder-
ate butyrylcholinesterase inhibition during initial investigations.[31]
This prompted us to develop a first total synthesis of racemic
muraricine (rac‐7) for providing sufficient amounts for further
pharmacological characterization.
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Based on our recently published racemic synthesis of the
bisbenzylisoquinoline alkaloids tetrandrine (1) and isotetrandrine,[32]
we herein present the first total synthesis of racemic muraricine
(rac‐7). Key steps of this approach are N‐acyl Pictet–Spengler
condensations for the formation of the tetrahydroisoquinoline
moieties and a copper‐catalyzed Ullmann coupling for the construc-
tion of the diaryl ether bridge.
Focus of the pharmacological evaluation of muraricine (rac‐7) is the
antiproliferative effect against several cancer cell lines, the evaluation
of toxicity to noncancerous cells, chemoresistance reversing property
by inhibition of the P‐glycoprotein (P‐gp), calcium channel‐blocking
activities, and antimicrobial effects.
2 | RESULTS AND DISCUSSION
2.1 | Chemistry
The total synthesis of racemic muraricine (rac‐7) requires the con-
struction of an N‐methylated 1‐benzyltetrahydroisoquinoline subunit,
which is connected via a diaryl ether bridge with a 1‐unsubstituted
N‐methylated tetrahydroisoquinoline. Very recently, we reported
on a new modular total racemic synthesis[32] of tetrandrine (1) and
isotetrandrine, for which we optimized both the diaryl ether synthesis
(Ullmann coupling) and the construction of N‐methylated 1‐benzylte-
trahydroisoquinolines using methoxystyrenes as arylacetaldehyde
equivalents in N‐acyl Pictet–Spengler condensations. Conveniently,
one intermediate of this (iso)tetrandrine synthesis (8; compound no.
19 in Ref. [32]) lends itself to be used as a precursor of racemic
muraricine (rac‐7). Compound 8 is readily available in high‐yielding
steps starting from two commercially available substituted benzalde-
hydes (4‐(benzyloxy)benzaldehyde, 3‐bromo‐4,5‐dimethoxybenzalde-
hyde) and one arylethylamine (vanillin‐derived 4‐hydroxy‐3‐methoxy-
phenethylamine). A detailed scheme on the preparation of
intermediate 8 is presented in the Supporting Information Data.
Trifluoroacetic acid‐mediated N‐acyl Pictet–Spengler reaction
of racemic 8 with paraformaldehyde in dichloromethane gave a
mixture of the ethoxycarbonyl‐protected tetrahydroisoquinoline
9a and a side product with an identical mass. Most likely, the minor
component is the regioisomer, 9b, resulting from two possible
directions of cyclization of the 3,4,5‐trisubstituted arylethyl-
amine derivative 8 (Scheme 1). The ratio of the products 9a:9b is
69:31, as determined by high‐performance liquid chroma-
tography (HPLC). The formation of regioisomers in electrophilic
cyclizations such as Pictet–Spengler reactions is a known problem,
which in certain cases can be controlled by solvent‐directed
approaches.[33,34] When conducting N‐acyl Pictet–Spengler con-
densation in polar solvents such as trifluoroethanol or methanol
following Kayhan's protocol,[34] the reaction unfortunately pro-
ceeded notably slower and was incomplete. From the obtained
mixture, the desired isomer 9a was isolated in good yield (68%)
readily by flash column chromatography (FCC). This regioisomer
9a could be unambiguously identified by 2D nuclear magnetic re-
sonance (NMR) experiments (heteronuclear multiple bond corre-
lation [HMBC] of 9a and by nuclear Overhauser effect
spectroscopy [NOESY] experiments of rac‐7, respectively). Finally,
bis‐carbamate 9a was converted to racemic muraricine (rac‐7) in
23% yield by simultaneous reduction of both ethoxycarbonyl
groups to N‐methyl groups using lithium alanate (Scheme 1). The
NMR data of product rac‐7 were in full agreement with the data
F IGURE 1 Bisbenzylisoquinoline alkaloids and naturally occurring seco‐analogues
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published for the natural alkaloid 7.[31] The proposed structure of
isolated muraricine (7) has herewith been confirmed.
2.2 | Pharmacology
As already mentioned, the only reported biological activity of mur-
aricine (7) is a moderate butyrylcholinesterase inhibition.[31] As var-
ious biological activities have been described for the class of
bisbenzylisoquinoline and benzylisoquinoline alkaloids as discussed
above, we submitted synthetic rac‐7 to our screening systems for
antiproliferative/cytotoxic, chemoresistance reversing, and anti-
microbial and calcium channel‐modulating activities.
2.2.1 | Antiproliferative activity
Antiproliferative effects of rac‐7 were investigated against
hepatocellular carcinoma (HepG2), colorectal adenocarcinoma
(HCT‐15), and bladder carcinoma (T24) cell lines and determined
by CellTiter‐Blue® assay. The bisbenzylisoquinoline alkaloid
tetrandrine (1) was used as a reference compound, whereas
tetrandrine (1) showed significant activity against the three tumor
cell lines; the truncated analogue rac‐7 did only show very low
antiproliferative effects and no cytotoxic activity (Figure 2). These
findings add to results of a structure–activity relationship study by
Kupchan and Altland.[9] In this investigation, both macrocyclic
bisbenzylisoquinolines and seco‐analogues which retained a
SCHEME 1 Total synthesis of racemic
muraricine (rac‐7). DCM, dichloromethane; rt,
room temperature; TFA, trifluoroacetic acid;
THF, tetrahydrofuran
F IGURE 2 Antiproliferative effects of rac‐7 on hepatocellular carcinoma (HepG2), colorectal adenocarcinoma (HCT‐15) and bladder
carcinoma (T24) cell lines were determined by CellTiter‐Blue® assay. Cells were incubated with the respective concentrations for 72 hr and
proliferation is shown as percentage of vehicle control after subtraction of the zero value. Tetrandrine (1) served as control. Line graphs display
mean ± SEM of three independent experiments. DMSO, dimethyl sulfoxide; SEM, standard error of the mean
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diaryl ether bridge connecting both benzyl groups showed
antiproliferative/cytotoxic effects, whereas trivial monomeric
benzyltetrahydroisoquinolines were virtually inactive.
2.2.2 | Toxicity
As tetrandrine (1) and other bisbenzylisoquinoline alkaloids are
also known to cause severe toxicity in liver[35–38] and lungs, [39–41] we
investigated whether rac‐7 is toxic to noncancerous cells. For that
purpose, human umbilical vein endothelial cells (HUVECs) were treated
with 10, 20, and 50 µM for 6 hr and cell viability was assessed by
quantifying the intracellular adenosine triphosphate (ATP) content. As
expected, tetrandrine (1) strongly and dose‐dependently affected
the viability of HUVECs. In contrast, no significant toxicity to en-
dothelial cells was observed upon rac‐7 treatment (Figure 3).
2.2.3 | Inhibition of P‐gp
As pointed out, rac‐7 does not have direct antitumor effects. Hence,
we aimed to evaluate its potential as an add‐on in combination
therapy. Natural alkaloids have been shown to improve the response
to several antitumor drugs by targeting the P‐gp.[10,11,42] P‐gp
facilitates the efflux of cytostatic drugs and thereby represents a
major cause of treatment failure and resistance to common cancer
therapeutics.[10] As no clinically approved treatment options target-
ing P‐gp are available so far, there is a need for identifying novel,
safe, and efficacious P‐gp inhibitors. Inhibition of P‐gp is mostly
described for macrocyclic bisbenzylisoquinolines like tetrandrine
(1)[42,43] and related alkaloids,[10] but also for some seco‐analogues,
such as dauricine and daurisoline.[44,45] Therefore, we investi-
gated the influence of rac‐7 on the accumulation of the P‐gp
model substrate calcein‐acetoxymethyl (AM) in vincristine‐resistant
CEM (VCR‐R CEM) cells, leukemia cells that overexpress P‐gp.
We found a dose‐dependent increase of calcein fluorescence
(Figure 4a–c). Although the inhibition of P‐gp‐mediated calcein‐AM
efflux was weaker than that of the known inhibitor verapamil
(Figure 4b,c), P‐gp could be identified as a target of rac‐7
(Figure 4a,c). Verapamil was used as a positive control as the treat-
ment did not affect cell viability under the chosen conditions. Con-
sequently, P‐gp inhibitory activity can be achieved by suitably
decorated open‐chain mimetics (seco‐analogues) of complex, macro-
cyclic bisbenzylisoquinolines. To test if a combination of VCR with
rac‐7 provides a therapeutic benefit, apoptosis of VCR‐R CEM cells
was evaluated. For both tested concentrations of VCR (0.1 and
1 µM), significantly increased apoptosis rates were detected when
it was combined with nontoxic concentrations of rac‐7 (25 µM;
Figure 4d). Taken together, these results demonstrate that rac‐7
represents a nontoxic seco‐analogue of tetrandrine (1) with the po-
tential to overcome drug resistance in cancer. P‐gp‐mediated drug
efflux is not only implicated in tumor therapy but also represents a
hurdle for the treatment of other diseases such as HIV and bacterial
infections.[11] Eradication of HIV reservoirs in the central nervous
system, for instance, is partly prevented by efflux transporters at the
blood–brain barrier, including P‐gp.[46] Consequently, this study
provides the basis for further investigating the potential of rac‐7 to
overcome resistance mechanisms by the efflux transporter P‐gp.
2.2.4 | Calcium imaging
To determine whether rac‐7 is an inhibitor of the calcium channel,
two‐pore channel 2 (TPC2), Ca2+‐imaging experiments were per-
formed using the recently published TPC2 activator TPC2‐A1‐N.[47]
The response of TPC2‐A1‐N in HEK293 cells stably expressing
TPC2L11A/L12A was not blocked by rac‐7 compared with a dimethyl
sulfoxide (DMSO) control, whereas tetrandrine was able to block
the activation (Figure 5a,b). Hence, rac‐7 does not show inhibitory
activity on TPC2.
2.2.5 | Antimicrobial activity
We tested rac‐7 for antimicrobial activity in a standard agar diffusion
assay against Gram‐positive (Streptococcus entericus, Staphylococcus
equorum) and Gram‐negative bacteria (Escherichia coli, Pseudomonas
marginalis), and against fungi (Yarrowia lipolytica, Saccharomyces cere-
visiae). There was no zone of inhibition observed in any experiment;
consequently, rac‐7 does not exhibit antimicrobial activity against the
above‐listed germs.
3 | CONCLUSION
In summary, we have developed the first total synthesis of racemic
muraricine (rac‐7) in a total of 10 steps. The overall yield amounts to
F IGURE 3 Acute toxicity to noncancerous human umbilical vein
endothelial cells is shown. Cells were treated for 6 hr with rac‐7 and
tetrandrine (1) (10, 20, 50 µM) for 6 hr. Cell viability was determined
by quantifying the cellular adenosine triphosphate content applying a
CellTiter‐Glo® cell assay and is displayed as percentage of vehicle
control as mean ± standard error of the mean of three independent
experiments (one‐way analysis of variance followed by Tukey's
multiple comparison test; **p < .01, ***p < .001)
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3.8% along the longest sequence. We further investigated biological
activities of this natural product and hereby focused on targets
that are already known for the class of (bis)benzylisoquinoline
alkaloids. Neither antiproliferative, antimicrobial, nor TPC2‐blocking
activity in Ca2+‐imaging experiments could be detected, whereas rac‐
muraricine could be identified as an inhibitor of P‐gp, an important
factor in the mechanism of multidrug resistance of tumors. Although
the inhibitory effect of muraricine on this efflux pump is only mod-
erate, significantly increased apoptosis rates were observed in
combination with VCR. Hence, rac‐muraricine was able to overcome
drug resistance to a commonly used chemotherapeutic drug. More-
over, no acute cytotoxicity to healthy human cells (HUVEC) in con-
centrations higher than that required for reversing chemoresistance
was detected for rac‐muraricine. These findings suggest that murar-
icine may serve as a potential lead structure in the development of
new nontoxic P‐gp inhibitors. Based on our synthetic approach,
systematic structure variations of muraricine can be part of future
drug design projects as the clinical need of P‐gp inhibitors for the




All solvents and reagents were purchased from commercial suppliers
and were used without further purification, unless mentioned other-
wise. Thin‐layer chromatography was carried out on 0.2mm silica gel
polyester plates with a fluorescence indicator (POLYGRAM SIL G/
UV254; Macherey‐Nagel). NMR spectra were recorded with a 400‐MHz
(400MHz for 1H and 101MHz for 13C) or 600‐MHz Bruker BioSpin
Avance spectrometer (599MHz for 1H and 151MHz for 13C). Peak
assignments were based on 2D NMR experiments using standard pulse
programs (correlation spectroscopy [COSY], heteronuclear multiple
quantum correlation/heteronuclear single quantum correlation [HSQC/
HMQC], distortionless enhancement of polarization transfer [DEPT],
HMBC, and NOESY). Chemical shifts were referenced to the
residual solvent signal (CDCl3: δH = 7.26 ppm, δC = 77.16 ppm). For the
(a) (b)
(c) (d)
F IGURE 4 (a,b) Retention of the P‐glycoprotein model substrate calcein‐AM in vincristine‐resistant CEM (VCR‐R CEM) cells was determined
by flow cytometry. Cells were incubated with calcein‐AM, in the presence or absence of increasing concentrations of rac‐7 and the positive
control verapamil (1, 10, 20, and 50 µM). Histograms of cell populations are shown. The experiment was performed in triplicate and one
representative experiment is shown. (c) Quantification and statistical analysis of data from (a,b). Bar graph displays mean ± SEM of three
independent experiments (one‐way ANOVA followed by Tukey's multiple comparison test; **p < .01, ***p < .001). (d) Percentage of apoptotic
cells is shown. VCR‐R CEM cells were treated with VCR (0.1 and 1 µM) with or without rac‐7 (25 µM) for 48 hr. Apoptotic cells were quantified
by propidium iodide staining and flow cytometry. Bar graph displays mean ± SEM of three independent experiments (one‐way ANOVA followed
by Tukey's multiple comparison test; *p < .05, ***p < .001). AM, acetoxymethyl; ANOVA, analysis of variance; DMSO, dimethyl sulfoxide; FITC,
fluorescein isothiocyanate; ns, not significant; SEM, standard error of the mean
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characterization of rotamers, a temperature program was employed for
recording both 1D and 2D spectra. Hereby, chemical shifts were re-
ferenced to the signal of tetramethylsilane in deuterated tetra-
chloroethane (Tcl2 [100°C]: δH = 5.92 ppm, δC = 74.0 ppm). Infrared (IR)
spectra were recorded using a Jasco FT/IR‐4100 (type A) instrument
equipped with a diamond attenuated total reflection (ATR) unit (Jasco
PRO450‐S). High‐resolution mass spectra (HRMS) were recorded using
a Jeol MStation 700 or JMS‐GCmate II Jeol instrument for electron
impact ionization. Thermo Finnigan LTQ was used for electrospray io-
nization (ESI). HPLC purity was determined using Infinity Lab Poroshell
120EC‐C18 and 120CN‐C18 columns (2.7 µm, 100 × 3.0mm), de-
tected at 210 and 254 nm. Reaction monitoring by mass spectrometry
was performed by atmospheric‐pressure solids analysis probe via
atmospheric‐pressure chemical ionization on an Advion expression
LC‐MS device. Purification by FCC was performed using Merck Silica gel
60 (0.040–0.063mm, 230–400 mesh ASTM). For quantitative analysis
of compounds 9a/9b, as well as for determination of the purity of all
compounds, HPLC was performed on an Agilent Zorbax Eclipse Plus
C18 column (5.0 µm, 150 × 4.6mm) using the following methods: an
eluent system as indicated below; flow 0.8ml/min; temperature 50°C;
Agilent 1100/1200 diode array detector (λ = 210 nm).
The InChI codes of compounds 9a and rac‐7 together with some
biological activity data are provided as Supporting Information Data.
4.1.2 | Synthesis of N,N′‐bisnor‐muraricine
bis(ethylcarbamate) (9a)
Intermediate 8 (53.0 mg, 0.0871 mmol) was dissolved in 1.5 ml
dichloromethane, and paraformaldehyde (5.2 mg, 0.174 mmol,
2.0 eq) was added. The mixture was cooled to 0°C, and
trifluoroacetic acid (65 µl, 0.871 mmol, 10.0 eq) was slowly added.
The reaction mixture was allowed to warm up to ambient
temperature and stirred for 2 hr. Then, 1.0 ml of a saturated
NaHCO3 solution was added for neutralization and the mixture
was extracted with dichloromethane (3 × 10 ml). The combined
organic phases were dried over anhydrous Na2SO4 and con-
centrated in vacuo. Purification by FCC (20% ethyl acetate in di-
chloromethane, Rf = 0.14) gave the title compound as a white solid
(36.8 mg, 0.0593 mmol, 68%). Mp: 91.0–93.0°C. 1H NMR, COSY
(400MHz, Tcl2, 100°C) δ [ppm] = 6.80–6.75 (m, 2H, 10‐H, 14‐H),
6.68 (s, 1H, 5‐H), 6.61–6.57 (m, 2H, 11‐H, 13‐H), 6.51 (s, 1H, 5′‐H),
6.03 (s, 1H, 8‐H), 4.95 (t, J = 6.6 Hz, 1H, 1‐H), 4.41 (d, J = 17.1 Hz,
1H, 1′‐H), 4.29 (d, J = 17.1 Hz, 1H, 1′‐H), 4.13 (q, J = 7.1 Hz, 2H,
′OCH2CH3), 4.04 (q, J = 7.1 Hz, 2H, OCH2CH3), 3.87 (s, 3H, 6‐
OCH3), 3.88–3.82 (m, 1H, 3‐H), 3.82 (s, 3H, 6′‐OCH3), 3.62–3.57
(m, 1H, 3′‐H), 3.59 (s, 3H, 7′‐OCH3), 3.34–3.25 (m, 1H, 3‐H), 2.91
(dd, J = 13.6, 6.0 Hz, 1H, α‐H), 2.79–2.72 (m, 4H, α‐H, 4′‐H, 4‐H),
2.61 (dt, J = 16.0, 5.2 Hz, 1H, 4‐H), 1.23 (t, J = 7.1 Hz, 3H, 2′‐
NCOOCH2CH3), 1.17 (t, J = 7.1 Hz, 3H, 2‐NCOOCH2CH3). 13C
NMR, HSQC, HMBC (101 MHz, Tcl2, 100°C) δ [ppm] = 156.0
(′C═O), 155.5 (C═O), 154.4 (C‐12), 152.4 (C‐6′), 148.5 (C‐6), 146.2
(C‐7), 145.9 (C‐8′), 140.6 (C‐7′), 130.6 (C‐10, C‐14), 130.4 (C‐9),
130.2 (C‐4a′), 129.3 (C‐8a), 128.6 (C‐4a), 120.2 (C‐8a′), 115.4 (C‐
11, C‐13), 114.9 (C‐8), 113.9 (C‐5), 109.8 (C‐5′), 61.4 (′OCH2CH3),
61.2 (OCH2CH3), 60.7 (7′‐OCH3), 56.9 (6‐OCH3), 56.6 (6′‐OCH3),
56.3 (C‐1), 42.3 (C‐α), 41.5 (C‐1′ and C‐3′), 39.1 (C‐3), 28.9 (C‐4′),
28.2 (C‐4), 14.70 (2′‐NCOOCH2CH3), 14.66 (2‐NCOOCH2CH3).
IR (ATR): ṽ [cm−1] = 2,925, 2,855, 1,670, 1,612, 1,513, 1,425,
1,236, 1,108, 1,023, 823, 769. Purity (HPLC) = 76% (λ = 210 nm)
(70% acetonitrile, 30% water). HRMS (ESI): m/z calcd for
[C34H40N2O9+ H]
+ 621.2807, found: 621.2806.
F IGURE 5 Ca2+‐imaging results of rac‐7, tetrandrine (1), and a DMSO control using the TPC2 activator TPC2‐A1‐N. (a) Representative Ca2+
signals recorded from HEK293 cells stably expressing TPC2L11A/L12A–RFP. After applying rac‐7 (10 µM; blue lines, n = 19 single cells),
tetrandrine (1, 10 µM; gray lines, n = 17 single cells) or DMSO (0.1% in HBS; red lines, n = 16 single cells) and monitoring the signal for 400 s,
cells were stimulated with TPC2‐A1‐N (10 µM) and further recorded for 400 s. Means are represented as highlighted lines, whereas single‐cell
traces of each experiment are in the background. (b) Statistical analysis of the maximal change in the Fura‐2 ratio (mean ± SEM) with the number
of independent experiments in parentheses. An unpaired t‐test was applied. DMSO, dimethyl sulfoxide; HBS, HEPES‐buffered solution; ns, not
significant; RFP, red fluorescent protein
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4.1.3 | Synthesis of racemic muraricine (rac‐7)
Lithium alanate (25.7 mg, 0.677mmol, 12.0 eq) was suspended in
1.0 ml anhydrous tetrahydrofuran (THF) under nitrogen atmosphere.
A solution of 9a (35.0 mg, 0.0564mmol) in anhydrous THF was added
dropwise and the resulting mixture was heated to 50°C for 3 hr. The
reaction mixture was cooled to 0°C and slowly quenched with water.
After alkalizing with a saturated NaHCO3 solution, the mixture was
extracted with ethyl acetate (3 × 10ml). The combined organic pha-
ses were dried over anhydrous Na2SO4 and concentrated in vacuo.
Purification by FCC (10% methanol and 2% triethylamine in ethyl
acetate, Rf = 0.22) gave the title compound as a beige solid (8.0mg,
0.0158mmol, 23%). Mp: 63.0–65.0°C (Ref. [31]: no melting point
given). 1H NMR, COSY, NOESY (400MHz [600MHz for NOESY],
CDCl3) δ [ppm] = 6.66 (s, 1H, 5‐H), 6.60 (d, J = 8.0 Hz, 2H, 10‐H, 14‐H),
6.53 (d, J = 8.0 Hz, 2H, 11‐H, 13‐H), 6.47 (s, 1H, 5′‐H), 4.83 (s, 1H,
8‐H), 3.89 (s, 3H, 6‐OCH3), 3.80 (s, 3H, 6′‐OCH3), 3.83–3.76 (m, 1H,
1′‐H), 3.58 (dd, J = 10.5, 3.0 Hz, 1H, 1‐H), 3.39 (s, 3H, 7′‐OCH3),
3.41–3.31 (m, 3H, α‐H, 3‐H, 4′‐H), 3.29–3.22 (m, 1H, 1′‐H), 3.12 (dd,
J = 11.0, 5.4 Hz, 1H, 3′‐H), 3.03–2.93 (m, 2H, 3‐H, 4‐H), 2.87–2.75 (m,
1H, 4‐H), 2.70 (d, J = 16.6 Hz, 1H, 4′‐H), 2.62 (s, 3H, 2‐NCH3), 2.61 (s,
3H, 2′‐NCH3), 2.53 (t, J = 11.8 Hz, 1H, α‐H), 2.47–2.38 (m, 1H, 3′‐H).
13C NMR, HSQC, HMBC (101MHz, CDCl3) δ [ppm] = 156.4 (C‐12),
152.1 (C‐6′), 147.6 (C‐6), 144.2 (C‐7), 144.1 (C‐8′), 138.9 (C‐7′), 130.9
(C‐10, C‐14), 129.7 (C‐9), 129.0 (C‐4a′), 126.1 (C‐8a), 125.6 (C‐4a),
118.8 (C‐8a′), 118.3 (C‐11, C‐13), 115.1 (C‐8), 111.9 (C‐5), 108.2
(C‐5′), 65.2 (C‐1), 60.2 (7′‐OCH3), 56.2 (6‐OCH3), 56.1 (6′‐OCH3),
53.0 (C‐1′), 52.4 (C‐3′), 45.6 (2′‐NCH3), 45.5 (C‐3), 41.8 (2‐NCH3),
39.6 (C‐α), 28.2 (C‐4′), 24.6 (C‐4). IR (ATR): ṽ [cm−1] = 2,925, 2,850,
1,611, 1,512, 1,453, 1,259, 1,118, 1,064, 834, 796. Purity (HPLC) ≥
95% (λ = 210 nm) (80% MeOH, 20% water, buffer pH 9). HRMS (ESI):
m/z calcd for [C30H36N2O5+H]
+ 505.2697, found: 505.2697.
4.2 | Biological assays
4.2.1 | Cell lines and culture
HCT‐15 cells were purchased from ATCC. T24 cells were obtained
from Dr. B. Mayer (Surgical Clinic, Ludwig‐Maximilians‐University
[LMU], Munich). VCR‐R CEM cells were kindly provided by Prof. Maria
Kavallaris (University of New South Wales, Australia). HepG2 cells
were obtained from German Research Centre of Biological Material
(DSMZ). HepG2 and T24 cells were cultivated with Dulbecco's mod-
ified Eagle's medium (DMEM; PAN Biotech), HCT‐15 and VCR‐R CEM
cells were cultivated with RPMI‐1640 (PAN Biotech), and were used
supplemented with 10% fetal calf serum (FCS; PAA Laboratories
GmbH). HUVECs were purchased from PromoCell and cultivated with
Endothelial Cell Growth Medium Kit Enhanced (PELO Biotech)
supplemented with 10% FCS (PAA Laboratories GmbH) and 1%
penicillin/streptomycin/amphotericin B (all purchased from PAN
Biotech). HUVECs were cultured for a maximum of six passages. All
cells were cultured at 37°C with 5% CO2 with constant humidity.
4.2.2 | Cell proliferation assays
Antiproliferative effects were assessed by CellTiter‐Blue cell viability
assay as described previously.[48] Cells were seeded at the following
densities: HepG2: 5 × 103 cells/well, HCT‐15: 3 × 103 cells/well, T24:
10 × 103 cells/well.
4.2.3 | Acute toxicity assay
HUVECs were seeded at a density of 10 × 103 cells/well of a 96‐well
plate and allowed to adhere overnight. On the following day, cells
were treated with the indicated concentrations of the respective
compounds for 6 hr. Cellular ATP content was quantified by
CellTiter‐Glo® cell viability assay (Promega) as indicated by the
manufacturer. Luminescence at 560 nm was recorded with an Orion
II Microplate Luminometer (Berthold Detection Systems).
4.2.4 | Calcein‐AM retention assay
The protocol was adapted from Robey et al.[42] Briefly, VCR‐R CEM
cells were seeded at a density of 0.15 × 106 cells/well of a 12‐well
plate and incubated for 4 hr. Subsequently, calcein‐AM (200 nM;
Biomol) and the potential P‐gp inhibitors were added and incubated
for 30min. After incubation, cells were centrifuged (400g, 5 min),
washed with phosphate‐buffered saline and resuspended in RPMI‐
1640 without phenol red (PAN Biotech) containing the respective
concentration of the P‐gp inhibitor. Following a 60‐min incubation
time, calcein fluorescence was analyzed by flow cytometry on a
FACSCalibur™ (Becton Dickinson).
4.2.5 | Apoptosis assay
VCR‐R CEM cells were seeded at a density of 0.125 × 106 cells/
well of a 24‐well plate and incubated for 4 hr. Treatment was per-
formed with the indicated concentrations for 48 hr. Apoptosis was
determined by propidium iodide staining as described before[49] on
FACSCalibur.
4.2.6 | Ca2+ imaging
Single‐cell Ca2+‐imaging experiments were performed using
Fura‐2 as previously described.[50] HEK293 cells stably expressing
TPC2L11A/L12A–RFP (generated according to Gerndt et al.[47]) were
cultured at 37°C with 5% of CO2 in DMEM (Thermo Fisher Scientific),
supplemented with 10% fetal bovine serum, 100U/ml penicillin, and
0.1mg/ml streptomycin. Cells were plated onto poly‐L‐lysine (Sigma‐
Aldrich)‐coated glass coverslips and grown for 2–3 days. For Ca2+‐
imaging experiments, cells were loaded for 1 hr at room temperature
with Fura‐2 AM (4.0 µM) and 0.005% (v/v) pluronic acid (both from
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Thermo Fisher Scientific) in HEPES‐buffered solution (HBS) comprising
138mM NaCl, 6mM KCl, 2mM MgCl2, 2mM CaCl2, 10mM HEPES,
and 5.5mM D‐glucose (adjusted to pH 7.4 with NaOH). After loading,
cells were washed with HBS and mounted in an imaging chamber. All
recordings were performed in HBS. Ca2+ imaging was performed using
a Leica DMi8 live cell microscope. Fura‐2 was excited at 340/380 nm.
Emitted fluorescence was captured using a 515‐nm long‐pass filter.
Compounds were prediluted in DMSO and stored as 10mM stock
solutions at −20°C, not exceeding 3 months. Working solutions were
prepared directly before using by dilution with HBS.
4.2.7 | Agar diffusion assay
The bacteria and fungi, purchased from DSMZ, were cultivated on an
AC agar (Sigma‐Aldrich). Six‐millimeter paper discs, impregnated with
30 µg of the tested compound or reference drug (tetracyclin/clo-
trimazole; both as a 1% [m/V] stock solution in DMSO) were placed
on the agar. The bacteria media were incubated for 24 hr at 32°C,
the fungi media for 48 hr at 28°C and the diameter of the zone of
inhibition (mm) was registered. Tests were performed in triplicate.
4.2.8 | Statistical analysis
The GraphPad Prism software was used for statistical analysis. For
some experiments, results were normalized to controls as indicated.
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